go-v.orgdoi

Etanercept for the treatment of axial spondyloarthritis

I-H Song, Joachim Sieper · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.17
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

The introduction of etanercept (ETN; Enbrel®), and other TNF-blockers, has revolutionized the treatment of patients with ankylosing spondylitis. ETN, as with other approved TNF-blockers, shows good efficacy in treating spinal disease, especially if patients are treated early. Furthermore, studies involving ETN demonstrate good long-term efficacy.

This review summarizes the data on ETN in the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, and discusses topics such as its efficacy in treating extra-articular manifestations, dose modifications and immunogenicity of ETN, and switching between ETN and other TNF-blockers, as well as radiographic progression and safety.

Open the resolved locator · 10.4155/cli.13.17

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 04:10 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.17
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.